Drug intelligence / Profile preview

DXLr120

Development stage: Unknown
Lead developer: Daxor
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

DXLr120 is a proprietary 5% human serum albumin (HSA) solution developed by Daxor Corporation, currently in Phase 2 clinical development for the treatment of heart failure. It is designed to be used as a volume expander that increases intravascular oncotic pressure, thereby drawing fluid from the interstitial space into the circulation to optimize blood volume. Daxor's strategy involves pairing DXLr120 with its BVA-100 (Blood Volume Analyzer) diagnostic tool to facilitate "precision fluid management," allowing for individualized dosing of albumin to correct specific volume deficits. This integrated approach aims to improve clinical outcomes in congestive heart failure and other conditions characterized by fluid imbalance.

Other names: 5% Human Serum Albumin

Beyond the preview

Go deeper on DXLr120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DXLr120.

Explore the full profile